Research ArticleCORONAVIRUS

The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates

See allHide authors and affiliations

Science Translational Medicine  12 May 2021:
Vol. 13, Issue 593, eabf1906
DOI: 10.1126/scitranslmed.abf1906

Materials and Methods

Fig. S1. Recombinant expression, biophysical characterization, and binding kinetics.

Fig. S2. Epitope binning heatmap.

Fig. S3. Biolayer interferometry measurements of Fab-spike binding kinetics.

Fig. S4. Epitope binning communities for 24 selected antibodies.

Fig. S5. Structural assessment of antibody epitopes.

Fig. S6. Cryo-EM structure validation.

Fig. S7. Timeline, screening, and sequence analysis.

Table S1. Epitope binding domains and affinities.

Table S2. Selected mAb information.

Table S3. Hydrogen/deuterium exchange data summary.

Table S4. Summary of viral neutralization data.

Table S5. Gross pathology findings.

Table S6. Statistical analyses for impact of LY-CoV555 on viral loads in SARS-CoV-2–challenged rhesus macaques.

Table S7. Serum human IgG concentrations and AUC0-6days after intravenous administration of LY-CoV555 or control IgG to rhesus macaques before and during SARS-CoV-2 challenge.

Table S8. BALF and estimated ELF fluid concentrations after intravenous administration of LY-CoV555 or control IgG to rhesus macaques during SARS-CoV-2 challenge.

Table S9. Cryo-EM data collection and refinement statistics.

Table S10. Crystallographic statistics.

Data file S1. SARS-CoV-2 genomic RNA in rhesus model of prophylaxis after administration of LY-CoV555 via the intravenous route.

References (8487)